
Loading, please wait...

Loading, please wait...

The JAK2V617F mutation detection is a critical step in the diagnostic pathway for BCR-ABL1-negative myeloproliferative neoplasms (MPNs). This specific point mutation in the Janus Kinase 2 gene leads to a gain-of-function effect, which drives the uncontrolled proliferation of myeloid cells. Therefore, clinicians require highly sensitive and reproducible assays to identify this mutation accurately for effective patient management.
A recent study evaluated the Primerdesign quantitative allele-specific amplification (Quasa) kit to determine its efficacy in clinical settings. Researchers compared the Quasa kit against established real-time PCR methods on the Bio-Rad CFX 96 platform. Consequently, the results demonstrated a 100% concordance in qualitative outcomes between the test methods. Moreover, the assay confirmed an analytical sensitivity of 0.1%, which is essential for detecting low-level mutations in early-stage disease.
The study also addressed the precision of the kit through rigorous intra-assay and inter-assay testing. Repeatability and reproducibility were confirmed using the WHO 1st International Reference Panel. Furthermore, the kit offers potential for quantitative analysis when laboratories analyze samples in duplicate. This versatility makes it a valuable asset for diagnostic laboratories interested in offering robust mutational testing.
As molecular testing becomes more accessible, the availability of commercial kits like the Quasa assay simplifies the standardization of results across different centers. Specifically, the high sensitivity ensures that very few cases go undetected, which is vital for early intervention. In addition, the quantitative capability may assist in monitoring treatment response or disease progression in the future.
The validation study confirmed an analytical sensitivity of 0.1%, allowing for the detection of even low-abundance mutations in genomic samples.
Yes, while primarily qualitative, the study indicates the kit has the potential for quantitative analysis when samples are processed in duplicate, facilitating mutation burden assessment.
The study found 100% concordance between the Quasa kit and real-time PCR with melting curve analysis, indicating that it is a highly reliable alternative.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. It should not be used for diagnosing or treating a health problem or disease. Clinicians should use their professional judgment and consider individual patient circumstances. Refer to the latest local and national guidelines for clinical practice.
References
Vaz D et al. Validation of the Primerdesign Quantitative Allele Specific Amplification Kit for the Detection of JAK2V617F Mutation. J Clin Lab Anal. 2026 Feb 19. doi: 10.1002/jcla.70180. PMID: 41711098.
Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
Vannucchi AM, et al. The JAK2 V617F mutation: Some answers and many new questions. Leukemia. 2006;20(9):1477-1481.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A validation study confirms the Primerdesign Quasa kit is a sensitive and reliable tool for JAK2V617F mutation detection in myeloproliferative neoplasms....
8 months ago

A breakthrough LC-MS/MS technique provides rapid, green quantification of polar pesticide residues like glyphosate across 13 foods. Dietary risk assessment shows negligible toxicity, while discarding initial tea infusions removes up to 99.2% of chemical traces.
Today

Delhi is undergoing a major healthcare overhaul with enhanced Ayushman Bharat insurance up to ₹10 lakh, increased MBBS and PG medical training seats, expanded primary network mandirs, new tertiary neuro-ICUs, and public-private reproductive technology initiatives to build a resilient, preventative healthcare model.
Today

Aon forecasts India's healthcare inflation will ease to 10.1% in 2027 from 11.5% in 2026. Despite moderation, healthcare expenses continue to outpace general inflation, propelled by non-communicable diseases, advanced medical therapeutics, and expanding utilization patterns across diverse patient populations.
Today

Non-union fractures occur in 2-5% of cases, causing significant disability and cost. Conservative modalities such as LIPUS, PEMF, and focused ESWT offer non-surgical healing options for defects up to 5-10 mm when adequate mechanical stability exists without infection.
Yesterday

A crossover trial reveals that acute resistance exercise at 80% 1RM markedly reduces circulating asprosin, enhances insulin sensitivity, and blunts appetite in women with and without obesity, establishing high-intensity lifting as an effective non-pharmacological metabolic therapy.
Today